Research Analysts’ Recent Ratings Updates for GRAIL (GRAL)

GRAIL (NASDAQ: GRAL) has recently received a number of price target changes and ratings updates:

• 4/21/2026 – GRAIL had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/11/2026 – GRAIL was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/10/2026 – GRAIL is now covered by Piper Sandler. They set a “neutral” rating and a $54.00 price target on the stock.
• 4/10/2026 – GRAIL is now covered by Mizuho. They set a “neutral” rating and a $58.00 price target on the stock.
• 3/30/2026 – GRAIL had its price target lowered by Guggenheim from $130.00 to $75.00. They now have a “buy” rating on the stock.
• 3/18/2026 – GRAIL was upgraded by TD Cowen from “hold” to “buy”. They now have a $65.00 price target on the stock.

Insider Buying and Selling at GRAIL

In other news, CEO Robert P. Ragusa sold 123,502 shares of GRAIL stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total transaction of $6,165,219.84. Following the completion of the transaction, the chief executive officer directly owned 518,582 shares in the company, valued at $25,887,613.44. This trade represents a 19.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Aaron Freidin sold 45,806 shares of the business’s stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the sale, the chief financial officer directly owned 260,669 shares of the company’s stock, valued at approximately $13,012,596.48. The trade was a 14.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 310,267 shares of company stock valued at $15,485,396. Corporate insiders own 1.85% of the company’s stock.

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.